Online Inquiry
ENMD-2076
SPC-00795
CAS No. 934353-76-1
| Size | Price |
| 10 mM (1 mL in DMSO) | Online Inquiry |
| 5 mg | Online Inquiry |
| 10 mg | Online Inquiry |
| 50 mg | Online Inquiry |
| 200 mg | Online Inquiry |
| Bulk Size | Online Inquiry |
FLT3 inhibitor ; Aurora Kinase inhibitor ; VEGFR inhibitor ; FGFR inhibitor ; PDGFR inhibitor ; Src inhibitor ; CSF-1R inhibitor ; Apoptosis related activator
| Description |
|---|
| ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM, which induces apoptosis and G2/M phase arrest. Phase 2. |
| Product Details | |
|---|---|
| CAS No. | CAS No. 934353-76-1 |
| Description | ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM, which induces apoptosis and G2/M phase arrest. Phase 2. |
| Formula | C21H25N7 |
| Molecular Weight | 375.47 |
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
| Synonyms | N/A |
| SMILES | CC1=CC(=NN1)NC2=CC(=NC(=N2)C=CC3=CC=CC=C3)N4CCN(CC4)C |
| Solubility | DMSO |
| Usage | |
|---|---|
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.